Evidence map›Paper›PMID 36302749›Full record

ArticleCell death & disease2022

Mutated lncRNA increase the risk of type 2 diabetes by promoting β cell dysfunction and insulin resistance.

Wan-Hui Guo, Qi Guo, Ya-Lin Liu, Dan-Dan Yan, Li Jin, Rong Zhang, Jing Yan, Xiang-Hang Luo, Mi Yang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Mettl14-mediated mJournal of endocrinological investigation · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. PTBP1 as a potential regulator of disease.Molecular and cellular biochemistry · 2024
    Review
  9. PARN Maintains RNA Stability to Regulate Insulin Maturation and GSIS in Pancreatic β Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Wan-Hui Guo *Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, P.R. China.ORCID 0000-0003-1629-7630
Qi Guo *Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, P.R. China.
Ya-Lin LiuDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, P.R. China.
Dan-Dan YanShanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 200233, Shanghai, P.R. China.
Li JinShanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 200233, Shanghai, P.R. China.
Rong ZhangShanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 200233, Shanghai, P.R. China.
Jing YanShanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Centre for Diabetes, Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 200233, Shanghai, P.R. China. jingyan_1216@vip.163.com.
Xiang-Hang LuoDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, P.R. China. xianghangluo@csu.edu.cn.
Mi YangDepartment of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, P.R. China. ym2405@csu.edu.cn.ORCID 0000-0003-3015-672X
Central South University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Islet β cell dysfunction and insulin resistance are the main pathogenesis of type 2 diabetes (T2D), but the mechanism remains unclear. Here we identify a rs3819316 C > T mutation in lncRNA Reg1cp mainly expressed in islets associated with an increased risk of T2D. Analyses in 16,113 Chinese adults reveal that Mut-Reg1cp individuals had higher incidence of T2D and presented impaired insulin secretion as well as increased insulin resistance. Mice with islet β cell specific Mut-Reg1cp knock-in have more severe β cell dysfunction and insulin resistance. Mass spectrometry assay of proteins after RNA pulldown demonstrate that Mut-Reg1cp directly binds to polypyrimidine tract binding protein 1 (PTBP1), further immunofluorescence staining, western blot analysis, qPCR analysis and glucose stimulated insulin secretion test reveal that Mut-Reg1cp disrupts the stabilization of insulin mRNA by inhibiting the phosphorylation of PTBP1 in β cells. Furthermore, islet derived exosomes transfer Mut-Reg1cp into peripheral tissue, which then promote insulin resistance by inhibiting AdipoR1 translation and adiponectin signaling. Our findings identify a novel mutation in lncRNA involved in the pathogenesis of T2D, and reveal a new mechanism for the development of T2D.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceInsulin-Secreting CellsIslets of LangerhansRNA, Long NoncodingAnimalsHumansInsulinMiceInsulinRNA, Long Noncoding

Identifiers

PMID36302749
PMCPMC9613878
OpenAlexW4307450005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.